Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.00M | $-1.49M | $-0.94 |
| 2024 | $917.2K | $690.5K | $0.43 |
| 2023 | $-70.5K | $-811.6K | $-0.51 |
| 2022 | $1.13M | $-3.36M | $-2.09 |
| 2021 | $1.43M | $1.44M | $0.90 |
Social Signal Score
Valuation
BHVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsprnewswire.com·4d ago·Positive
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA N
View source ↗